At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 16, 2026 at 07:00 ET
Olema Oncology reported financial results for 2025, showing increased net losses due to higher R&D spending on late-stage trials for palazestrant and early development of OP-3136. The company raised $218.5 million in a follow-on offering, ending the year with $505.4 million in cash. Key catalysts ahead include top-line data from the Phase 3 OPERA-01 trial in fall 2026 and initial clinical results for OP-3136 in Q2 2026.
- Net loss for 2025 was $162.5 million, up from $129.5 million in 2024, driven by increased R&D spending.
- GAAP R&D expenses rose to $157.7 million in 2025 from $124.5 million in 2024, including a $10M milestone payment (vs. $5M in 2024).
- Company raised $218.5 million in gross proceeds from a public offering, ending 2025 with $505.4 million in cash and marketable securities.
- Top-line data from Phase 3 OPERA-01 trial expected in fall 2026; initial OP-3136 data expected Q2 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access